16JUN

WHO issues its first fungal blueprint

2 min read

10:26UTC

The World Health Organization published its first blueprint on fungal disease on 1 July, estimating more than 300 million people suffer serious fungal illness each year.

← Back to Bundibugyo's fork stays open Jump to analysis ↓

ScienceAssessed

Key takeaway

WHO's first fungal blueprint names a 300-million-case burden that global resistance strategy had tracked only in bacteria.

The World Health Organization (WHO) published its first dedicated Blueprint on fungal disease and antifungal resistance on Wednesday 1 July, estimating that more than 300 million people suffer serious fungal disease each year ¹. The report says plainly that fungal disease is "largely absent from national health plans, global burden-of-disease estimates" and from mainstream antimicrobial resistance (AMR) strategy.

The blueprint sets four action domains and 12 national entry points, building on WHO's existing fungal priority pathogens list, which includes Candida auris, a drug-resistant yeast that spreads in hospitals and shrugs off first-line antifungals. Antimicrobial resistance is the broader field of pathogens surviving the drugs meant to kill them, and until now its surveillance counted only bacteria.

WHO's GLASS surveillance found in 2025 that one in six bacterial infections is now resistant , and the ten-year GAP-AMR plan adopted in May set targets for bacterial deaths alone . Fungi sat outside both. The blueprint is WHO's first attempt to name that omission and hand countries a governance scaffold for closing it.

Deep Analysis

In plain English

Antimicrobial resistance is when infections stop responding to the drugs normally used to treat them. Until now, global tracking of this problem has focused almost entirely on bacteria, even though fungal infections can be just as resistant and just as deadly. On 1 July, the World Health Organization published its first-ever policy document dedicated to fungal disease and antifungal resistance, estimating that more than 300 million people suffer a serious fungal infection every year. Candida auris, a drug-resistant yeast that spreads in hospitals, is one of the pathogens named in the Blueprint.

What could happen next?

Meaning
Fungal disease's inclusion in a WHO framework does not itself fund the laboratory capacity needed to track it in the countries carrying the highest burden.

Source Landscape

This story draws on neutral-leaning sources from Switzerland

Switzerland

Primary parallel: WHO's 2017 bacterial priority pathogens list named the resistance threat years before dedicated antifungal or antibacterial R&D funding followed, the same list-first, funding-later sequence this fungal Blueprint now begins.

Counter-parallel: The 2022 mpox PHEIC drew emergency funding and vaccine allocation within months of declaration, because an active outbreak with rising case counts creates faster political urgency than a standing disease-burden estimate does, a contrast suggesting this Blueprint may move at the bacterial list's slower pace rather than an outbreak's faster one.

Consensus view: The WHO Blueprint frames fungal disease as invisible by policy design, not by epidemiology, since the decade-long Global Action Plan on Antimicrobial Resistance adopted in May 2026 and the GLASS surveillance system both track bacterial resistance only, leaving an estimated 300 million annual serious fungal cases outside any global reporting mechanism.

Counter-view: Africa CDC's ARILAC laboratory-capacity programme, which found only 1.3% of assessed African laboratories conduct routine AMR testing of any kind, suggests the Blueprint's surveillance ambitions are unreachable in the same countries carrying the heaviest fungal burden until basic lab infrastructure is funded first.

Key tension: Whether naming fungal disease in a global framework accelerates funding toward the labs that need it, or simply adds an unfunded reporting requirement to systems already failing on bacterial surveillance.

Sources:WHO

Mentions:World Health Organization →WHO Blueprint on fungal disease and antifungal resistance →Candida auris →ARILAC →Africa CDC →PHEIC →

First Reported In

Update #10 · Ebola's responders are now the casualties

WHO· 14 Jul 2026

Read original →

Causes and effects

Caused by

One in six infections beats the drug

WHO GLASS's bacterial-only resistance findings left fungal disease outside AMR surveillance until this Blueprint.

Occurred 1 Jun 2026

Read story →

WHA79 adopts a 10-year AMR plan

The ten-year GAP-AMR plan adopted in May addressed bacterial resistance only, a gap the fungal Blueprint now names explicitly.

Occurred 23 May 2026

Read story →

This Event

WHO issues its first fungal blueprint

WHO's blueprint pulls fungal disease into a resistance strategy that until now tracked only bacteria.

Different Perspectives

Chinese health authorities

China reported three human H9N2 cases to WHO between 10 and 16 July: two four-year-olds recovered, a 44-year-old man remains in intensive care, the first severity signal in a cluster that has produced 173 cases and 2 deaths globally since 2015. The subtype is distinct from the H5N1 series this topic otherwise tracks.

US public health authorities

CIDRAP and Dr Andrew Racine, president of the American Academy of Pediatrics, call 2026's 2,318 confirmed measles cases by 24 July the worst year since 1991's 2,126. Zero deaths against three in 2025 and a 7% hospitalisation rate, down from 11%, show record case counts have not brought record severity.

CEPI

CEPI put an rVSV-platform vaccine candidate specific to Bundibugyo ebolavirus into trial-production on 31 July, developed by Hilleman Laboratories with MSD manufacturing and IAVI's reference virus, funded up to $8.5m. Eleven weeks into the third-largest Ebola outbreak on record, this is the first species-matched candidate; the licensed vaccine covers only Zaire ebolavirus.

Médecins Sans Frontières

MSF reports sexual-violence care in Ituri is almost non-existent, with 7 of 14 health centres closed or relocated by fighting, as Panzi Hospital logs 646 new survivors in six months, an 85% rise. Withdrawn US funding for post-exposure prophylaxis has left clinics across three provinces without PEP kits for months, a crisis running alongside Ebola, not caused by it.

DRC health workers at Elikya Ebola Treatment Centre

Staff at DRC's Elikya Ebola Treatment Centre walked out on 25 July over unpaid wages, the second such action after Rwampara, while unconfirmed suspects occupy up to 64% of the country's isolation beds awaiting lab results. Workers are absorbing a response that has grown faster than its payroll and its labs.

Uganda's Ministry of Health

Uganda's ministry says it discharged its last confirmed patient on 16 June, completed every contact's 21-day follow-up, and declared the country Ebola-free on 28 July, exactly 42 days later. It names Hon. Dr Chris Baryomunsi, Minister of Health, as overseeing a 20-case, 2-death outbreak it now considers closed.